Silverback Therapeutics, Inc. (NasdaqGM: SBTX) Loss Submission Form

Kuznicki Law is investigating the proposed merger of Silverback Therapeutics, Inc. (the “Company”) (NasdaqGM: SBTX) with ARS Pharmaceuticals, Inc. pursuant to which Silverback shareholders will end up owning just approximately 37% of the combined company, subject to certain adjustments. Kuznicki Law is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.